RGNX
NASDAQ
$10.32
Regenxbio Inc (RGNX)
REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $24.27 (+135.17%)
Market Cap
$633M
Free Cash Flow Yield
-37.33%
Beta (5Y)
1.83
Price Chart
Valuation
Market Cap$633M
P/S7.23
P/B30.14
Profitability
Total Revenue (TTM)$88M
Gross Profit (TTM)-$173M
EBITDA-$241M
Operating Margin-1304%
EPS-$5.69
Financial Health
Free Cash Flow Yield-37.33%
Growth & Risk
EPS 5Y CAGR+13.05%
Revenue 5Y CAGR-10.83%
FCF 5Y CAGR+15.93%
Beta (5Y)1.83
Sharpe Ratio0.63